These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27262556)

  • 1. Limiting Free Pricing of New Innovative Drugs After Launch: A Necessity for Payers?
    Gandjour A
    Appl Health Econ Health Policy; 2016 Oct; 14(5):507-9. PubMed ID: 27262556
    [No Abstract]   [Full Text] [Related]  

  • 2. The challenge of paying for cost-effective cures.
    Zettler PJ; Fuse Brown EC
    Am J Manag Care; 2017 Jan; 23(1):62-64. PubMed ID: 28141931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UK strong arms industry over drug pricing.
    Mitchell P
    Nat Biotechnol; 2008 Aug; 26(8):846-7. PubMed ID: 18688221
    [No Abstract]   [Full Text] [Related]  

  • 4. Value-Based Pharmaceutical Contracts: Value for Whom?
    Kannarkat JT; Good CB; Parekh N
    Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New NICE criteria for drug access.
    Fricker J
    Lancet Oncol; 2017 May; 18(5):576. PubMed ID: 28343973
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead.
    Kaltenboeck A
    Value Health; 2020 Apr; 23(4):421-424. PubMed ID: 32327158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Policy and Practice for Value-Based Pricing.
    Augustovski F; McClellan MB
    Value Health; 2019 Jun; 22(6S):S4-S6. PubMed ID: 31200805
    [No Abstract]   [Full Text] [Related]  

  • 9. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value-based drug pricing in the Biden era: Opportunities and prospects.
    Neumann PJ; Ollendorf DA; Cohen JT
    Health Serv Res; 2021 Dec; 56(6):1093-1099. PubMed ID: 34085289
    [No Abstract]   [Full Text] [Related]  

  • 11. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Globalization, pharmaceutical pricing, and South African health policy: managing confrontation with U.S. firms and politicians.
    Bond P
    Int J Health Serv; 1999; 29(4):765-92. PubMed ID: 10615573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'The pros and cons of a single euro-price for drugs' and 'the economics of parallel trade'.
    Rovira J
    Pharmacoeconomics; 1998 Jul; 14(1):135-7. PubMed ID: 10182191
    [No Abstract]   [Full Text] [Related]  

  • 15. Whatever happened to the Norwegian Medical Need Clause? Lessons for current debates in EU pharmaceutical regulation.
    Brooks E; Geyer R
    Sociol Health Illn; 2016 May; 38(4):576-91. PubMed ID: 26564268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Euro MPs refuse to approve medicines agency's accounts until they tighten rules on conflicts of interest.
    Watson R
    BMJ; 2012 May; 344():e3495. PubMed ID: 22597355
    [No Abstract]   [Full Text] [Related]  

  • 17. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What Is Possible and What Is Not? The Development of a Legal Framework for Drug Pricing Mechanisms in the EU.
    Ernst G
    Eur J Health Law; 2019 Apr; 26(2):120-140. PubMed ID: 31059472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovation-Innovation Tradeoffs in Drug Pricing.
    Sachs RE; Frakt AB
    Ann Intern Med; 2016 Dec; 165(12):871-872. PubMed ID: 27723887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.